Insulet Co. (NASDAQ:PODD) Shares Acquired by Scientech Research LLC

Scientech Research LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 181.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,978 shares of the medical instruments supplier's stock after purchasing an additional 5,783 shares during the period. Scientech Research LLC's holdings in Insulet were worth $1,812,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PODD. Capital Research Global Investors lifted its position in shares of Insulet by 19.7% during the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier's stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Insulet during the second quarter worth $99,978,000. Baillie Gifford & Co. lifted its position in shares of Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier's stock worth $380,607,000 after purchasing an additional 443,783 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Insulet by 56.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier's stock worth $190,623,000 after purchasing an additional 316,649 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in Insulet by 206.9% in the first quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier's stock valued at $73,632,000 after acquiring an additional 289,591 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PODD. Redburn Atlantic began coverage on shares of Insulet in a report on Thursday, May 30th. They issued a "buy" rating and a $235.00 price target on the stock. Piper Sandler upped their price target on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. BTIG Research cut their price target on shares of Insulet from $270.00 to $250.00 and set a "buy" rating on the stock in a report on Friday, August 9th. Barclays upped their price target on shares of Insulet from $200.00 to $220.00 and gave the company an "equal weight" rating in a report on Monday, August 12th. Finally, OTR Global reaffirmed a "mixed" rating on shares of Insulet in a report on Monday, June 10th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $231.71.

Insulet Stock Down 1.4 %

Insulet stock opened at $235.43 on Friday. The company has a 50-day simple moving average of $206.07 and a 200-day simple moving average of $190.01. The firm has a market capitalization of $16.51 billion, a P/E ratio of 71.34, a P/E/G ratio of 4.47 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a one year low of $125.82 and a one year high of $243.98.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). The firm had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm's revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.38 EPS. As a group, equities analysts expect that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.